BlueWind Medical Announces Peer-Reviewed Data Showing Excellent Durability of Results for Revi® System at Two Years
PARK CITY, Utah, February 07, 2025--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and developer of the Revi® System, a patient-centric solution for urgency urinary incontinence (UUI), announced today the publication of two-year results from the pivotal OASIS study in the March 2025 issue of the Journal of Urology.
The OASIS study is a prospective, multicenter, single-arm, open-label clinical study of 151 adult women (mean age 58.8 years) with UUI (urgency urinary incontinence; overactive bladder-wet syndrome [OAB-wet]). The trial evaluated the efficacy and safety of Revi in treating UUI symptoms in patients with OAB-wet. Primary efficacy and safety endpoints were assessed at six and 12 months, with 97 participants consenting to and completing the 24-month assessment.
Key findings at two years demonstrate Revi's durable efficacy, highly favorable safety profile, and high patient satisfaction, supporting its use for treating UUI. Notably, a sustained therapy response was observed utilizing a more flexible provider and patient-driven schedule in year two (≥ two 30-minute sessions/week) compared to the first year (30-minute daily sessions). Patients averaged at least one treatment session on eight of 10 days, tailored to individual symptom needs.
The OASIS study's two-year analysis demonstrated that Revi provided sustained therapy response with:
Durable reduction in UUI episodes, with 79% of participants experiencing a ≥50% reduction in UUI episodes and 56% achieving a ≥75% reduction in UUI
High satisfaction rates, with 97% of the participants satisfied and 97% reporting feeling "better" to "very much better"
Freedom from leaks with 28% of patients dry on a three-day voiding diary
Substantial reduction in large volume urgency-related leaks, one of the most debilitating aspects of UUI, from 0.9/day to 0.1/day
An excellent safety profile, with no (0%) device- or procedure-related serious adverse events, no device migrations, and no device revision procedures
"What sets Revi apart is its patient centricity. The system allows patients to tailor treatment intervals to their symptoms and providers to individualize treatment plans to each patient," said John Heesakkers, M.D., Chairman of the Department of Urology of the Maastricht University Medical Center in the Netherlands. "It is encouraging to see that the OASIS study long-term data continues to validate the Revi System as a durable and effective treatment for UUI."
With recent concerns about the potential link between anticholinergic agents and dementia risk, there is an increased need for flexible, non-pharmacologic treatment options. Revi is the first iTNM device for the treatment of UUI labeled for use without prior failure of more conservative therapies. Revi, with its unique label, offers an effective treatment option, supported by the newly updated 2024 Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder from the American Urological Association and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, which advocates for early consideration of minimally invasive therapy and emphasizes shared decision-making in OAB and UUI management.
"The two-year study results affirm the Revi System's significant impact in improving OAB and UUI symptoms and underscore its innovation and effectiveness as a minimally invasive neuromodulation option," said Roger Dmochowski, M.D., Chief Medical Advisor, BlueWind Medical. "Our commitment remains steadfast to enhancing treatment options and elevating the quality of life for people grappling with UUI."
For more information on BlueWind Medical and the Revi System, please visit bluewindmedical.com.
About BlueWind Medical Ltd.
BlueWind Medical is transforming the field of neuromodulation therapy through the development of innovative, patient-centric medical technology for the treatment of disease. BlueWind is committed to enhancing the quality of life and overall well-being of patients with an initial focus on those living with urge urinary incontinence (UUI). BlueWind's Revi® System is the first and only implantable tibial neuromodulation device activated by a battery-operated external wearable to receive FDA clearance for patients with UUI. Revi is the only neuromodulation therapy on the market that allows physicians to use their discretion to determine whether the patient should fail or not tolerate more conservative treatments before using the Revi System rather than mandating "step-therapy."
For additional information about BlueWind Medical, please visit bluewindmedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207113202/en/
Contacts
Media Contact For BlueWind MedicalAlexander Romero-Wilsonalexander@healthandcommerce.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
10 hours ago
- CNN
HHS: How we're fixing the organ transplant system that betrayed America
EDITOR'S NOTE: Thomas Engels is the administrator of the Health Resources and Services Administration at the US Department of Health and Human Services. Organ donation can be a profound last gift of life. I think about the future my grandson will inherit, especially when it comes to something as urgent and deeply personal as organ donation or transplant. If he or someone he loves needs an organ transplant, I want him to know the system is safe, fair and worthy of his trust. Sadly, our US Department of Health and Human Services investigation of the organ transplant system has revealed everyone's worst nightmare: a systemic disregard for the sanctity of life. We found numerous cases of medical providers starting the organ donation process on living patients. In response, we have threatened to shut down a large organ procurement organization unless it implements our corrective action requirements. We have also imposed strict reporting protocols for the organ transplant system and required that families and hospitals receive clear, complete information about the donation process. How did the organ transplant system fail to protect some of our most vulnerable Americans? It operated behind closed doors for decades, dominated by a single private contractor. Too many patients waited for answers that never came, and families whose loved ones' organs were pursued while still alive were left with nowhere to turn when such atrocities occurred. Only a sick system prioritizes profit over patients. That ended thanks to the leadership of President Donald Trump and HHS Secretary Robert F. Kennedy Jr. At the Health Resources and Services Administration (HRSA), we are undertaking a sweeping overhaul of the Organ Procurement and Transplantation Network (OPTN), the entity legally responsible for managing the organ waitlist and allocation nationwide. Our reforms are rooted in two fundamental truths: Patient safety is not optional, and every life is sacred. For far too long, patients, hospital staff or grieving families were forced to report serious safety concerns and misconduct to the very contractor managing the system. This left families unheard, frustrated or even silenced. That era is over. Now, under our new reforms, those concerns can come directly to the regulator HRSA. We brought federal oversight into the heart of the process, making it clear there will be no compromise on safety and accountability. We've also proposed new data requirements for organ procurement organizations (OPOs), requiring full documentation of every step in the donation process, from contact with hospitals to interactions with donor families. These reforms aren't just about performance tracking. They're about restoring safety and dignity to a system that lost sight of both. And when horrifying failures come to light, like the shocking case in Kentucky in which organ procurement was nearly performed on a patient who showed signs of life, we act immediately. For the first time, HRSA issued a corrective action plan to an OPO, and we will not hesitate to do it again. No American should ever have to wonder whether their life will be treated with reverence at the hospital. The systemic failures weren't just operational — they were structural. For nearly 40 years, OPTN was governed by a single private entity: the United Network for Organ Sharing (UNOS). We ended a monopoly that suppressed innovation, enabled conflicts of interest and delayed reform. HRSA conducted a historic national election to establish an independent OPTN Board of Directors. This new board includes transplant surgeons, living donors, organ recipients and advocates, bringing a range of expertise and experience to the forefront of reform. We are also modernizing the transplant system by expanding the pool of best-in-class vendors to expand the capacity and performance of the system. With bipartisan support, HRSA now has the authority to directly collect OPTN registration fees from transplant hospitals, helping sustain long-term reforms and reduce reliance on any single contractor. Our work is informed by conversations with transplant surgeons, patients, donor families, advocates and hospital staff. These voices have made one thing abundantly clear: Change cannot wait. Secretary Kennedy has demanded accountability across HHS, and President Trump has shown unwavering commitment to ending complacency in systems that cost lives. The old system operated behind closed doors. We opened them up. We are building a system that is ethical, transparent and centered on the sacred sanctity of life. There is more work to do, but we are making progress quickly, just like the rest of the Trump administration. We will not rest until every registered organ donor, patient and family have confidence in our nation's transplant system. Because that's what Americans deserve and what every life demands.
Yahoo
a day ago
- Yahoo
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. on Global Equity Briefing's Substack by Ray Myers. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc.'s share was trading at $118.97 as of July 31st. TMDX's trailing and forward P/E were 59.75 and 62.11 respectively according to Yahoo Finance. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. TransMedics is revolutionizing the organ transplant ecosystem through its Organ Care System, a technology designed to keep organs warm, oxygenated, and viable far longer than traditional cold storage. By tackling key bottlenecks—organ degradation, low utilization rates, and logistical constraints—Organ Care System significantly extends transplant windows and boosts usage rates. Clinical trial data highlights its transformative potential: expanded criteria lungs and hearts saw utilization jump to 87% and 81%, respectively, while DCD heart use rose from 0% to 89%. TMDX monetizes this impact through a razor-and-blade model—selling Organ Care System consoles and high-margin, single-use consumables—while providing end-to-end services through its National Organ Care System Program, a SaaS-like Organs as a Service platform. With 21 private jets, 17 procurement hubs, and trained staff, TMDX handles organ retrieval, transport, and maintenance, positioning itself as a logistics powerhouse in the transplant chain. The opportunity is vast: U.S. underutilization alone represents a $400M+ annual consumables revenue potential, and TMDX currently serves just 3% of the $39B global market expected by 2034. Future growth catalysts include a kidney Organ Care System by 2029, entry into international markets via a $200M facility in Italy, and scaling the National Organ Care System Program globally. Financially, the company achieved profitability in 2024, posting $441M in revenue and positive operating cash flow, though free cash flow remains negative due to capex-heavy expansion. Trading at a P/E of 91, investor returns hinge on continued execution, EU rollout, and successful kidney platform launch. If goals are met, the stock could double by 2030, but slower expansion or margin compression may limit upside. Previously, we covered a on TransMedics Group, Inc. by Oliver | MMMT Wealth in May 2025, which highlighted warm perfusion technology, strong execution, and real-time flight data as revenue indicators. The company's stock appreciated ~24% since Q1 outperformance played out. Ray Myers shares a similar view but emphasizes the SaaS-like NOP model and global expansion potential. TransMedics Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held TMDX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Yahoo
a day ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
